In an interview with FOX Business Network’s Maria Bartiromo, Lilly (NYSE:LLY) Diabetes President Enrique Conterno discussed the company’s new drug for patients with type-2 diabetes
Continue Reading Below
According to Conterno, a new study found that Jardiance reduces the risk of complications that kills patients with the disease.
“Jardiance was involved in a large cardiovascular trial involving more than 7,000 patients with type-2 diabetes and we basically saw, with Jardiance, a cardiovascular risk reduction as defined by stroke, heart attacks and cardiovascular deaths. This is most relevant because, as you said, heart issues are the number one cause of death for people with diabetes.”
Conterno said this is the first product to provide these kind of results.
“We clearly see these type of results as one of a kind and the very first product to be able to show this. We will characterize this as extremely good news for patients… for Lilly… Boehringer Ingelheim -- our partner in this venture,” he said.